S Ben-Horin

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. doi request reprint Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease
    Shomron Ben-Horin
    Dept of Gastroenterology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel
    J Crohns Colitis 5:555-8. 2011
  2. ncbi request reprint The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions
    Shomron Ben-Horin
    Department of Medicine F, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Am J Med 118:636-40. 2005
  3. doi request reprint The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
    Shomron Ben-Horin
    Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Gut 60:41-8. 2011
  4. doi request reprint Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection
    Shomron Ben-Horin
    Sheba Medical Center, Tel Aviv University, Israel
    J Crohns Colitis 4:194-8. 2010
  5. doi request reprint Optimizing anti-TNF treatments in inflammatory bowel disease
    Shomron Ben-Horin
    IBD Service, Department of Gastroenterology, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel Electronic address
    Autoimmun Rev 13:24-30. 2014
  6. doi request reprint Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease
    Shomron Ben-Horin
    Department of Gastroenterology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Clin Gastroenterol Hepatol 11:444-7. 2013
  7. doi request reprint The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
    S Ben-Horin
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel
    Aliment Pharmacol Ther 35:714-22. 2012
  8. doi request reprint Travel-associated health risks for patients with inflammatory bowel disease
    Shomron Ben-Horin
    Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Clin Gastroenterol Hepatol 10:160-5, 165.e1. 2012
  9. doi request reprint Review article: loss of response to anti-TNF treatments in Crohn's disease
    S Ben-Horin
    Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel
    Aliment Pharmacol Ther 33:987-95. 2011
  10. doi request reprint Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection
    Shomron Ben-Horin
    Sheba Medical Center, Tel Aviv University, Israel
    Clin Gastroenterol Hepatol 7:981-7. 2009

Detail Information

Publications21

  1. doi request reprint Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease
    Shomron Ben-Horin
    Dept of Gastroenterology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel
    J Crohns Colitis 5:555-8. 2011
    ..Limited data suggest the absence of infliximab in breast milk, thereby implying the safety of this drug during breast-feeding. We aimed to re-evaluate the presence of infliximab in breast milk of nursing IBD patients...
  2. ncbi request reprint The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions
    Shomron Ben-Horin
    Department of Medicine F, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Am J Med 118:636-40. 2005
    ..Moreover, there is little data regarding the normal composition of the physiological pericardial fluid, which could serve as a reference for pathological effusions...
  3. doi request reprint The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
    Shomron Ben-Horin
    Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Gut 60:41-8. 2011
    ..To localise the immunogenic part of infliximab and evaluate the clinical usefulness of measuring antibodies against infliximab fragments...
  4. doi request reprint Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection
    Shomron Ben-Horin
    Sheba Medical Center, Tel Aviv University, Israel
    J Crohns Colitis 4:194-8. 2010
    ..difficile associated disease (CDAD), but the reason for this is unknown. We aimed to evaluate the rate of pseudomembranes in this population, identify predictive factors for pseudomembranes' presence and assess its clinical impact...
  5. doi request reprint Optimizing anti-TNF treatments in inflammatory bowel disease
    Shomron Ben-Horin
    IBD Service, Department of Gastroenterology, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel Electronic address
    Autoimmun Rev 13:24-30. 2014
    ..Failure of anti-TNF treatment in inflammatory bowel disease (IBD) patients can take on several forms, each posing distinct etio-pathogenic considerations and management dilemmas...
  6. doi request reprint Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease
    Shomron Ben-Horin
    Department of Gastroenterology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Clin Gastroenterol Hepatol 11:444-7. 2013
    ..The addition of immunomodulators to therapy might be helpful to patients who have lost response to anti-TNF agents owing to formation of antidrug antibodies...
  7. doi request reprint The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
    S Ben-Horin
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel
    Aliment Pharmacol Ther 35:714-22. 2012
    ..Anti-drug antibodies can be elicited by infliximab and adalimumab, but the rate of their decay after therapy is stopped is unknown...
  8. doi request reprint Travel-associated health risks for patients with inflammatory bowel disease
    Shomron Ben-Horin
    Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Clin Gastroenterol Hepatol 10:160-5, 165.e1. 2012
    ..There are few data on risk of travel for patients with inflammatory bowel disease (IBD). We assessed rates of illness while traveling among patients with IBD...
  9. doi request reprint Review article: loss of response to anti-TNF treatments in Crohn's disease
    S Ben-Horin
    Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel
    Aliment Pharmacol Ther 33:987-95. 2011
    ..Loss of response to anti-TNF agents in Crohn's disease is an emerging clinical problem...
  10. doi request reprint Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection
    Shomron Ben-Horin
    Sheba Medical Center, Tel Aviv University, Israel
    Clin Gastroenterol Hepatol 7:981-7. 2009
    ..We investigated the effects of combination therapy with antibiotics and immunomodulators in patients with IBD and C difficile infection...
  11. ncbi request reprint The outcome of a second preparation for colonoscopy after preparation failure in the first procedure
    Shomron Ben-Horin
    Current affiliations Department of Gastroenterology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Gastrointest Endosc 69:626-30. 2009
    ..There are scant data regarding the outcome of consecutive repeated procedures in patients who failed to adequately clean their colon for colonoscopy...
  12. doi request reprint Familial clustering of Crohn's disease in Israel: prevalence and association with disease severity
    Shomron Ben-Horin
    Gastroenterology Division, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Israel
    Inflamm Bowel Dis 15:171-5. 2009
    ..There is limited data addressing the severity of Crohn's disease (CD) in patients with a family history of inflammatory bowel disease (IBD) compared to sporadic cases...
  13. doi request reprint Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines
    S Ben-Horin
    Laboratory of Mucosal Immunology, Gastroenterology Department, Sheba Medical Center, Tel Hashomer 52621, Israel
    Gut 58:396-403. 2009
    ..The onset of the effect of thiopurines is delayed for several months. The aim of this study was to investigate immune mechanisms for this delay...
  14. pmc Flare-up of ulcerative colitis after systemic corticosteroids: a strong case for Strongyloides
    Shomron Ben-Horin
    Gastroenterology Department, Sheba Medical Center, Tel Hashomer 52621, Israel
    World J Gastroenterol 14:4413-5. 2008
    ..This case underscores the importance of considering Strongyloides in the work-up of flaring-up IBD patients, even if a history of residing or traveling to endemic areas is in the distant past...
  15. ncbi request reprint Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis
    Shomron Ben-Horin
    Department of Medicine, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Medicine (Baltimore) 85:49-53. 2006
    ..This grave diagnosis cannot be ruled out on the basis of any clinical parameter. Thus, a more extensive workup should probably be considered in this patient group...
  16. ncbi request reprint Diagnostic value of the biochemical composition of pericardial effusions in patients undergoing pericardiocentesis
    Shomron Ben-Horin
    Department of Medicine F, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Am J Cardiol 99:1294-7. 2007
    ..In conclusion, most PEs are exudates. The analysis of pericardial fluid biochemical and cell-count composition is generally not helpful for the diagnosis of most PEs...
  17. pmc Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation
    A Lahat
    Department of Gastroenterology, Chaim Sheba Medical Center affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Clin Exp Immunol 152:320-7. 2008
    ..These effects are mediated at least partly by inhibition of NF-kappaB signalling...
  18. doi request reprint Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines
    U Kopylov
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel
    Aliment Pharmacol Ther 36:145-50. 2012
    ..Moreover, data on VZV immunity in adult IBD patients or accuracy of VZV serological testing under immunomodulator treatment is sparse...
  19. ncbi request reprint The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease
    T Berdichevski
    Center for Liver Diseases, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel
    Infection 41:969-77. 2013
    ..We investigated whether the formation of pseudomembranes predicts a worse CDAD outcome...
  20. doi request reprint The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab
    U Kopylov
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Ramat Gan, Israel
    Aliment Pharmacol Ther 33:349-57. 2011
    ..Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks...